research use only

Foscenvivint (PRI-724) CBP/β-catenin Antagonist

Name: Foscenvivint (PRI-724)
Brand: Selleck Chemicals
SKU: S8968
Availability: InStock
Rating: 5 (32 reviews)

Cat.No.S8968

Foscenvivint (PRI-724) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP.

Chemical Structure

Molecular Weight: 658.64

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.12%

99.12

Products Often Used Together with Foscenvivint (PRI-724)

HS-173

It and HS-173 synergistically reduce the viability of FaDu cells.

LGK974 (WNT974)

It and LGK-974 exhibit antitumor properties in NET cell lines.

ICG-001

It and ICG-001 are antifibrotic compounds that inhibit Wnt signaling and prevent liver fibrosis.

Related Targets	JAK STAT TGF-beta/Smad ERK GSK-3 Casein Kinase Notch ROCK Hedgehog/Smoothened PKA Secretase PORCN OCT KLF Stemness kinase SFRP Fascin
Related Products	ICG-001 IWR-1-endo IWP-2 SKL2001 BML-284 (Wnt agonist 1) Salinomycin (from Streptomyces albus) FH535 PNU-74654 LF3 KYA1797K KY02111 iCRT3 Adavivint (SM04690) MSAB Isoquercitrin IQ-1 iCRT14 CCT251545 JW55 Methyl Vanillate M435-1279 WAY-262611 JW74 Non-phospho β-Catenin (Ser45) Antibody [K20N13] Zamaporvint (RXC004) DKK1 Antibody [K16J6] Tegatrabetan (BC-2059) TCF4/TCF7L2 Antibody [P1D24] TCF3/TCF7L1 Antibody [G18A14] Phospho-β-Catenin (Ser552) Antibody [K9A16]

Chemical Information, Storage & Stability

Molecular Weight	658.64	Formula	C₃₃H₃₅N₆O₇P	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1422253-38-0	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	C-82 prodrug, ICG-001 analog			Smiles	CC1C2N(C(C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (151.82 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.330mg/ml (5.06mM)	Taking the 1 mL working solution as an example, add 50 μL of 66.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.750mg/ml (5.69mM)	Taking the 1 mL working solution as an example, add 50 μL of 75 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	β-catenin ^[1] CBP ^[1]
In vivo	Foscenvivint (PRI-724) reduces liver fibrosis and hepatic hydroxyproline levels in HCV mice while attenuating αSMA induction. It leads to increased levels of matrix metalloproteinase (MMP)-8 mRNA in the liver, along with elevated levels of intrahepatic neutrophils and macrophages/monocytes. In conclusion, this compound ameliorates HCV-induced liver fibrosis in mice and is a drug candidate which possesses antifibrotic effect.^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/28336942/ [2] https://pubmed.ncbi.nlm.nih.gov/35163171/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04688034	Completed	Liver Cirrhosis	Kiminori Kimura MD\|Japan Agency for Medical Research and Development\|Ohara Pharmaceutical Co. Ltd.\|Komagome Hospital	March 15 2021	Phase 1
NCT04047160	Completed	Primary Biliary Cholangitis (PBC)\|Liver Cirrhosis Biliary	Kiminori Kimura MD\|Ohara Pharmaceutical Co. Ltd.\|Japan Agency for Medical Research and Development\|Komagome Hospital	August 29 2019	Phase 1
NCT02195440	Completed	Hepatitis C Virus-infected Cirrhosis	Komagome Hospital\|Prism Pharma Co. Ltd.\|Japan Agency for Medical Research and Development	August 2014	Phase 1
NCT01764477	Completed	Advanced Pancreatic Cancer\|Metastatic Pancreatic Cancer\|Pancreatic Adenocarcinoma	Prism Pharma Co. Ltd.\|inVentiv Health Clinical	April 2013	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):